A Study of HS269 in Patients With Advanced Solid Tumors

NCT ID: NCT05058352

Last Updated: 2021-09-27

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-31
• Study Completion Date: 2023-04-30

Brief Summary

This is a Phase I, open-label, first in human study of HS269 tablet, a small molecule highly-selective RET Inhibitor. The dose-escalation study will assess the safety, tolerability, and pharmacokinetics of HS269 and determine the dose and schedule to be used in Phase II. Seventeen to thirty-six patients with advanced solid tumor may be enrolled in this study.

Conditions

Advanced Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HS269

Multiple doses of HS269 tablets

Group Type: EXPERIMENTAL

HS269

Intervention Type: DRUG

Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.

Interventions

HS269

Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. ≥18 years, no gender limit.

2. Patients with advanced solid tumors confirmed by histology or cytology fail to receive standard treatment, or there is no standard treatment, or standard treatment is not applicable at this stage.

3. At least one evaluable tumor lesion according to RECIST version 1.1.

4. ECOG≤ 1.

5. The estimated survival time was more than 3 months.

6. The function of all organs was good, the specific indexes were as follows:

Blood system (no transfusion or hematopoietic stimulating factor treatment within 14 days) i. #NEUT ≥1.5×109/L ii. PLT ≥90×109/L iii. HGB ≥85g/L Liver function i. TBIL ≤1.5×ULN ii. ALT ≤3×ULN; Patients with liver metastasis or liver cancer: ≤ 5 × ULN iii. AST ≤3×ULN; Patients with liver metastasis or liver cancer: ≤ 5 × ULN Renal function i. Ccr >50 ml/min（According to Cockcroft-Gault formula） Blood coagulation function i. APTT ≤1.5×ULN ii. INR ≤1.5×ULN

7. The subjects should be informed and agreed to the study before the start of the trial, and sign the written informed consent voluntarily.

Exclusion Criteria

1. Received anti-tumor treatments within 14 days or less than 5 half-lives (whichever is longer) before the first use of the study drug

2. Received blood transfusion, erythropoietin, recombinant human thrombopoietin or colony stimulating factor and other treatments within 7 days before receiving blood system examination during the screening period.

3. Received other unmarketed clinical study drugs or treatments within 4 weeks before the first use of the study drug.

4. Major organ surgery (excluding biopsy) or significant trauma occurred within 4 weeks before the first use of the study drug;

5. Systemic administration of glucocorticoids (prednisone > 10 mg / day or equivalent dose of the same drug) or other immunosuppressants within 14 days before the first use of the study drug; except for local, eye, intra articular, nasal and inhaled corticosteroids; short-term use of glucocorticoids for preventive treatment (e.g. prevention of contrast agent allergy)；

6. CYP1A2/P-gp potent inhibitors or potent inducers were used within 7 days before the first use of the study drug；

7. Resistance to selective RET inhibitors;

8. The adverse reactions of previous anti-tumor therapy have not yet recovered to CTCAE 5.0 grade evaluation ≤ 1 (except for the toxicity without safety risk judged by researchers such as alopecia)；

9. Patients with central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that the central nervous system metastasis or meningeal metastasis has not been controlled, which is not suitable for the study.

10. Have active infection and need systemic anti infection therapy；

11. Have a history of immunodeficiency, including HIV antibody test positive；

12. Active hepatitis B, allowing preventive antiviral treatment other than interferon; hepatitis C virus infection；

13. Present or past interstitial lung disease (except radiation-induced pulmonary fibrosis without hormone therapy)；

14. Poorly controlled diabetic patients.

15. Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to:

1. Serious abnormal cardiac rhythm or conduction, such as ventricular arrhythmia, Ⅱ - Ⅲ degree atrioventricular block, etc;

2. In the resting state, average QTcF≥480ms in 12 lead -ECG；

3. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other cardiovascular events of grade 3 or above occurred within 6 months before the first administration;

4. NYHA ≥II or LVEF<50％；

5. Hypertension beyond clinical control；

16. Could not take medication orally，or have severe gastrointestinal obstruction (such as gastrointestinal obstruction, gastrointestinal absorption)；

17. The third space effusion, which could not be controlled clinically, was not suitable for the study；

18. Mental disorder or poor compliance；

19. Eligible patients with fertility (male and female) do not agree to use reliable contraceptive methods (abstinence, condom, intrauterine device or ligation) with their partner during the trial and for at least 3 months after the last medication.

20. Female patients have a positive blood pregnancy test within 7 days before enrollment, or breastfeeding women;

21. The subjects were not suitable for the clinical study because of other serious systemic diseases or other reasons according to the investigator 's judgment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zhejiang Hisun Pharmaceutical Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Qiming Wang

Role: PRINCIPAL_INVESTIGATOR

Henan Provincial People's Hospital

Qi Dang

Role: PRINCIPAL_INVESTIGATOR

Shandong Cancer Hospital and Institute

Locations

Shanghai Pulmonary Hospital

Shanghai, , China

Countries

China

Central Contacts

Caicun Zhou

Role: CONTACT

caicunzhoudr@163.com

021-65115006

Wei Li

Role: CONTACT

leewluck@gmail.com

021-65115006

Facility Contacts

Caicun Zhou

Role: primary

Other Identifiers

HS269-Ⅰ-01

Identifier Type: -

Identifier Source: org_study_id